[go: up one dir, main page]

NO982588D0 - FremgangsmÕte for diagnose og behandling av plate epizelkarsinom - Google Patents

FremgangsmÕte for diagnose og behandling av plate epizelkarsinom

Info

Publication number
NO982588D0
NO982588D0 NO982588A NO982588A NO982588D0 NO 982588 D0 NO982588 D0 NO 982588D0 NO 982588 A NO982588 A NO 982588A NO 982588 A NO982588 A NO 982588A NO 982588 D0 NO982588 D0 NO 982588D0
Authority
NO
Norway
Prior art keywords
diagnosis
procedure
treatment
cell carcinoma
squamous cell
Prior art date
Application number
NO982588A
Other languages
English (en)
Other versions
NO982588L (no
NO319903B1 (no
Inventor
Karl-Heinz Heider
Guenter Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Original Assignee
Boehringer Ingelheim Int
Karlsruhe Forschzent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Boehringer Ingelheim Int, Karlsruhe Forschzent filed Critical Boehringer Ingelheim Int
Publication of NO982588D0 publication Critical patent/NO982588D0/no
Publication of NO982588L publication Critical patent/NO982588L/no
Publication of NO319903B1 publication Critical patent/NO319903B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19982588A 1995-12-06 1998-06-05 Anvendelse av et antistoffmolekyl for fremstilling av et farmasoytisk preparat for behandling av plateepitelkarsinom. NO319903B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17
PCT/EP1996/005448 WO1997021104A1 (de) 1995-12-06 1996-12-05 Verfahren zur diagnose und therapie von plattenepithelkarzinomen

Publications (3)

Publication Number Publication Date
NO982588D0 true NO982588D0 (no) 1998-06-05
NO982588L NO982588L (no) 1998-08-05
NO319903B1 NO319903B1 (no) 2005-09-26

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982588A NO319903B1 (no) 1995-12-06 1998-06-05 Anvendelse av et antistoffmolekyl for fremstilling av et farmasoytisk preparat for behandling av plateepitelkarsinom.

Country Status (26)

Country Link
EP (1) EP0865609B1 (no)
JP (1) JP2000502067A (no)
KR (1) KR100473824B1 (no)
CN (1) CN1151377C (no)
AR (1) AR004360A1 (no)
AT (1) ATE235056T1 (no)
AU (1) AU726704B2 (no)
BG (1) BG62985B1 (no)
BR (1) BR9611901A (no)
CA (1) CA2239709A1 (no)
CO (1) CO4520233A1 (no)
CZ (1) CZ174198A3 (no)
DE (1) DE59610248D1 (no)
DK (1) DK0865609T3 (no)
EE (1) EE03783B1 (no)
ES (1) ES2190484T3 (no)
HK (1) HK1011560A1 (no)
MX (1) MX9804459A (no)
NO (1) NO319903B1 (no)
NZ (1) NZ324314A (no)
PL (1) PL184521B1 (no)
PT (1) PT865609E (no)
SK (1) SK284378B6 (no)
TR (1) TR199801027T2 (no)
UY (1) UY24389A1 (no)
WO (1) WO1997021104A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
PE20021098A1 (es) * 2001-05-18 2003-02-11 Boehringer Ingelheim Int ANTICUERPOS ESPECIFICOS DE CD44v6
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
RS53327B (en) * 2010-02-04 2014-10-31 University Of Miami Monoclonal antibody to CD44, for use in the treatment of squamous cell carcinoma of the head and neck
US9218450B2 (en) * 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
CN112105643B (zh) * 2018-02-22 2023-09-26 普众发现医药科技(上海)有限公司 治疗性抗体及其应用
AU2023274919A1 (en) 2022-05-25 2024-12-05 Akiram Therapeutics Ab Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678487B2 (en) * 1993-06-18 1997-05-29 Oy Biotie Therapies Ltd Compositions and diagnostic methods using monoclonal antibodies against CD44v6
US6010865A (en) * 1993-06-22 2000-01-04 Boehringer Ingelheim International Gmbh Process for detecting a variant CD44 gene product
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
BG62985B1 (bg) 2000-12-29
TR199801027T2 (xx) 1998-10-21
EP0865609A1 (de) 1998-09-23
CO4520233A1 (es) 1997-10-15
JP2000502067A (ja) 2000-02-22
MX9804459A (es) 1998-09-30
AU1177397A (en) 1997-06-27
SK73698A3 (en) 1999-01-11
PL327066A1 (en) 1998-11-23
CN1151377C (zh) 2004-05-26
AU726704B2 (en) 2000-11-16
ES2190484T3 (es) 2003-08-01
HK1011560A1 (en) 1999-07-16
CZ174198A3 (cs) 1999-02-17
BG102513A (en) 1999-02-26
EE03783B1 (et) 2002-06-17
AR004360A1 (es) 1998-11-04
EP0865609B1 (de) 2003-03-19
DK0865609T3 (da) 2003-06-23
BR9611901A (pt) 1999-03-02
KR100473824B1 (ko) 2005-09-30
WO1997021104A1 (de) 1997-06-12
CN1207811A (zh) 1999-02-10
NO982588L (no) 1998-08-05
ATE235056T1 (de) 2003-04-15
UY24389A1 (es) 2001-10-25
NZ324314A (en) 2000-02-28
SK284378B6 (sk) 2005-02-04
PL184521B1 (pl) 2002-11-29
CA2239709A1 (en) 1997-06-12
DE59610248D1 (de) 2003-04-24
NO319903B1 (no) 2005-09-26
EE9800164A (et) 1998-12-15
PT865609E (pt) 2003-08-29
KR19990071952A (ko) 1999-09-27

Similar Documents

Publication Publication Date Title
NO982588D0 (no) FremgangsmÕte for diagnose og behandling av plate epizelkarsinom
DE60029812D1 (de) Diagnose von zellenproliferation sowie screeningverfahren für deren modulatore
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
DE69433564D1 (de) Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung
DE60033555D1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
ATE218890T1 (de) Bispezifische moleküle mit klinischer verwendbarkeit
ATE364089T1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
DE69841164D1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
ATE552270T1 (de) Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren
ATE403743T1 (de) Genetische veränderungen, die mit lungencarzinomen korrelieren
TR200001313T2 (tr) Protein etkileşimlerini ve fonksiyonel ilişkileri kaydeden tarama sistemleri
DE69507470D1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
DE69934324D1 (de) Behandlung von entzündungskrankheiten
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
WO2000012703A3 (en) Protein transport-associated molecules
DE60038894D1 (de) Screeningverfahren für geeignete wirkstoffe
ATE126830T1 (de) Verfahren zum nachweis von kleinzelligem carzinom und die verwendung von sequenzen, die acylpeptid- hydrolase codieren, für diesen zweck.
WO2000005374A3 (en) Molecules associated with cell proliferation
CA2415364A1 (en) Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors
DE69734890D1 (de) Rdgb-proteine
DE69931644D1 (de) Verfahren zur diagnose, feststellung, einstufung, darstellung sowie behandlung gynäkologischer krebserkrankungen
EP1095183A4 (en) DIAGNOSIS AND TREATMENT METHODS FOR LUNG CANCER
NO970130D0 (no) Oligomere bærermolekyler med definerte, innebygde markörgrupper og haptener
AU4121997A (en) Method for sorting antifungal molecules acting on the glucanosyltransferase activity